TABLE 4.
Sorafenib dose/day
|
P | ||
---|---|---|---|
800 mg (n=33) | 400 mg (n=66) | ||
Overall survival, months, mean | 7.8 | 7.1 | 0.14 |
Three-month radiological response (tumour burden) | |||
Stable | 6 (18) | 13 (20) | 1.0 |
Increased | 18 (55) | 30 (45) | 0.4 |
Decreased | 1 (3) | 4 (6) | 0.6 |
Unknown | 8 (24) | 19 (29) | 0.8 |
Disease control rate | 7 (21) | 17 (26) | 0.8 |
Three-month alpha-fetoprotein levels | |||
Stable | 5 (15) | 8 (12) | 0.7 |
Increased | 12 (37) | 25 (38) | 1.0 |
Decreased | 1 (3) | 10 (15) | 0.09 |
Unknown | 15 (45) | 23 (35) | 0.4 |
Data presented as n (%) unless otherwise indicated